complement C1q like 4Genealiases: C1QTNF11 · CTRP11
Q-omics provides the consensus-scored C1QL4 profile across patient tissues and cancer cell-line models. C1QL4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, C1QL4 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, C1QL4 RNA expression shows 14,302 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where C1QL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1QL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1QL4 survival associations across molecular data types. C1QL4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1QL4 RNA expression–survival associations across cancer types. High C1QL4 expression shows unfavorable associations in MESO, KICH, ACC and BLCA, but favorable associations in KIRC and OV. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for C1QL4 RNA expression.
This table summarizes C1QL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C1QL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1QL4 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LUSC, LUAD and UCEC. The HNSC box plot shows higher C1QL4 RNA expression in tumor versus normal tissue (log2 FC = +0.621, t-test p < 0.001).
This table shows molecular features associated with C1QL4 in patient tissues and cancer cell lines. In patient samples, C1QL4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C1QL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
